Figure - available via license: Creative Commons Attribution 4.0 International
Content may be subject to copyright.
ROP staging, zones, and disease course of studied patients
Source publication
Background
Anti-vascular endothelial growth factor (Anti-VEGF) therapy is now considered as one of standard therapies in approaching infants with retinopathy of prematurity (ROP). The purpose of this study was to assess the time to full retinal vascularization in infants with ROP who were treated with intravitreal bevacizumab (IVB).
Methods
This r...
Context in source publication
Context 1
... disease was present in 861/865 (99.6%) of eyes of which 186/861 (21.6%) were zone 1 and 675/861 (78.4%) were zone 2. Pre-treatment ROP stage was stage 3 in 830/864 (99.5%) of eyes, stage 2 in 33/864 eyes, and stage 1 in 2/864. Iris neo-vascularization was present in 54/864 (6.2%) of eyes at initial examination (Table 1). Seven hundred and ninety-seven eyes initially treated with IVB achieved regression of ROP without reactivation (797/865; 92.1%). ...Citations
... 39,63 In cases of areas inadvertently skipped by laser, signs of treatment failure manifest promptly and the time to retreatment (frequently given for incomplete regression instead of reactivation) is typically shorter in comparison with anti-VEGFs as previously stated. 78 Our data should be integrated with other factors also implicated in the time to retreatment such as the systemic conditions of the infant, like basal weight 56,76 or higher VEGF loads in aggressive ROP in order to choose the most adequate dose in each case. 5 Abnormalities of the anterior segment resulting in high myopia were initially seen in the eyes of infants enrolled in the Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) study who received retinal ablative therapy. ...
Background
To compare the choroidal thickness and vascular profile of premature infants with ROP (retinopathy of prematurity) using a handheld SD-OCT device.
Methods
We performed horizontal SD-OCT scans through the fovea in 115 eyes of 66 premature infants. Premature infants included 2 groups [infants with ROP requiring treatment (as treatment group) vs. infants without ROP or with ROP not- requiring treatment (as no-treatment group)] Choroidal thicknesses (CT) were measured at 5 points, including the fovea, 250 µm, and 500 µm mm nasal and temporal to the fovea. The choroidal vascularity index (CVI) and choroidal stromal index (CSI) were also calculated. The classification and regression tree (CRT) algorithm was used to predict the need for treatment based on all OCT characteristics.
Results
Mean CT was higher in 500 µm nasal to the fovea compared to temporal CT (275.8 ± 64.8 and 257.1 ± 57.07, P value < 0.03). No statistically significant difference was found regarding CVI, corrected CVI, and temporal and nasal CT in the treatment group versus the no-treatment group. The foveal CT was significantly lower in ROP patients with the plus disease compared to not-plus ROP (P value = 0.03. ANOVA, Bonferroni posthoc test). CT was not significantly different between plus and pre-plus patients (P-value = 0.9, ANOVA, Bonferroni posthoc test). No significant relationship was found between the stage of ROP and choroidal thickness (P value > 0.05, GEE). The decision tree analysis showed that in infants with ROP, the most important predictor for the need for treatment is CSI.
Conclusion
This study delineated the possible effectiveness of choroidal measurements as an additive to decision-making for ROP. We also demonstrated that choroidal involution is associated with the presence of plus disease, not with the stage of ROP. We demonstrated that choroidal measurements are very sensitive but not specific tools for assessing the need for treatment in ROP patients.
